Loading organizations...
§ Private Profile · San Francisco, CA, USA
Biotech startup developing AI foundation models for faster drug discovery, focused on de novo design of custom antibodies and molecules.
Chai Discovery is an artificial intelligence biotechnology company that develops foundation models to predict and reprogram biochemical interactions for accelerated drug discovery. The organization provides pharmaceutical customers with systems like Chai-1 and Chai-2, which enable the de novo design of custom antibodies and small molecules to tackle difficult therapeutic targets. The startup has raised over $225 million in total capital, reaching a $1.3 billion valuation following a $130 million Series B round in December 2025. This financing followed a $70 million Series A and a $30 million seed round, with venture funding supplied by prominent backers including General Catalyst, Menlo Ventures, Thrive Capital, and OpenAI. The enterprise also appointed former Pfizer executive Mikael Dolsten to its board of directors. Chai Discovery was founded in 2024 by Joshua Meier, Jack Dent, Matthew McPartlon, and Jacques Boitreaud.
Chai Discovery has raised $230.0M across 3 funding rounds.
Chai Discovery has raised $230.0M in total across 3 funding rounds.
Chai Discovery has raised $230.0M across 3 funding rounds. Most recently, it raised $130.0M Series B in December 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 15, 2025 | $130.0M Series B | Hemant Taneja, Annie Lamont | Lachy Groom, DIMENSION, Emerson Collective, Glade Brook Capital, Menlo Ventures, Neo, Sam Altman, SV Angel, Thrive Capital, Yosemite |
| Aug 1, 2025 | $70.0M Series A | Greg Yap | 8VC, Alkeon Capital, C2 Investment, Gaingels, Indeed.com, Innovation Endeavors, LGF, Menlo Ventures, Otherwise Fund, Paradigm, Stellar Capital, Thrive Capital, Y Combinator, Elad Gil, John Collison, Konstantin von Unger, Patrick Collison, Fred Ehrsam, Lachy Groom, Avenir, Data Collective, DIMENSION, Yuri Milner, Neo, OpenAI, SV Angel, Yosemite |
| Sep 1, 2024 | $30.0M Seed | 50 Partners, NEO, Outrun Ventures, Stellar Capital, Stellation Capital, Vibe Capital, Y Combinator, Kelvin Beachum Jr., Kevin Weil, Ron Pragides, Thibaud Elziere, William Levy |
Chai Discovery is a biotech startup founded in 2024 that builds AI foundation models to predict and reprogram interactions between biochemical molecules, enabling de novo antibody design and drug-like molecule creation.[1][2][5] It serves life sciences researchers and drug developers by tackling hard-to-drug targets, with products like Chai-1 and the advanced Chai-2 model, which improve success rates in designing custom antibodies from scratch.[2][5] The company has shown explosive growth, raising $30M in seed funding, followed by a $70M Series A, and a $130M Series B in December 2025 at a $1.3B valuation, totaling over $225M from top investors including OpenAI, Thrive Capital, General Catalyst, and Menlo Ventures.[1][2][4]
This momentum positions Chai Discovery as a leader in AI-driven drug discovery, accelerating the shift from traditional trial-and-error methods to precise, computational design of therapeutics.[2][5]
Chai Discovery was founded in 2024 in New York by Joshua Meier (CEO and co-founder, with prior experience in machine learning at Facebook and OpenAI) and Jack Dent (co-founder).[2][3] The idea emerged from Meier's expertise in AI research, aiming to create foundation models specifically tuned for biochemistry to predict molecular interactions and enable reprogramming for drug development.[1][2] Early traction came swiftly: within a year, the company launched Chai-1, secured $30M in seed funding from high-profile backers like OpenAI and Thrive Capital, and emerged from Neo's talent program, which has nurtured successes like Cognition and Pika Labs.[1][2] Pivotal moments include the $70M Series A in August 2025 led by Menlo Ventures and the recent $130M Series B, validating its rapid progress in de novo antibody design.[2][4]
Chai Discovery rides the AI-for-drug-discovery wave, where foundation models cut development timelines from years to months by simulating molecular behaviors at scale.[2] Timing is ideal amid surging investments in biotech AI—exemplified by peers like insitro—and post-ChatGPT AI hype extending to science, with Chai's OpenAI ties amplifying credibility.[1][2][3] Market forces favoring it include exploding demand for precision medicine, antibody therapeutics (a $200B+ market), and compute advancements enabling complex simulations.[2][5] It influences the ecosystem by democratizing access to advanced models (via "Get Access" offerings), inspiring AI-biotech hybrids, and proving Neo's talent pipeline yields unicorns like itself.[1][5]
Chai Discovery's trajectory—from 2024 seed to $1.3B valuation in 2025—signals it's poised to redefine antibody and drug design, with Chai-2 edging toward clinical-ready molecules.[2][5] Next steps likely include partnerships with pharma giants for real-world trials, model releases like Chai-3, and potential IPO as AI-biotech matures.[2] Trends like multimodal AI (integrating structure, sequence, function) and regulatory nods for AI-designed drugs will propel it, evolving its role from pioneer to infrastructure provider for the life sciences revolution—echoing its mission to engineer better molecules at atomic precision.[5]
Chai Discovery has raised $230.0M in total across 3 funding rounds.
Chai Discovery's investors include Hemant Taneja, Annie Lamont, Lachy Groom, DIMENSION, Emerson Collective, Glade Brook Capital, Menlo Ventures, Neo, Sam Altman, SV Angel, Thrive Capital, Yosemite.